Pharma and API maker (Lazertinib originator)
Yuhan Corporation
A top-tier Korean pharmaceutical company making prescription drugs, OTC medicines and household products. It out-licensed its lung-cancer drug Lazertinib to Janssen (now J&J) in 2018, and J&J's Rybrevant plus Lazcluze combination is now approved in the US, Europe, Japan and China, generating net-sales royalties. Yuhan shares part of the technology fees with the original developers Oscotec and Genosco. Its subsidiary Yuhan Chemical supplies HIV and hepatitis C active ingredients to Gilead and others.
000100.KS Updated Jul 12, 2026 2 AI consumers· 1 recurring
Per the valuechain.wiki graph, Yuhan Corporation is directly linked to 3 companies (1 supply, 2 revenue relationships) and reaches 3 companies within two hops; the links are backed by 7 dated sources, 4 of them primary filings (as of 2026-07-12).
Financials & Segments
- Total revenue · 2025 consolidated revenue KRW 2.19tn (+5.7% YoY), operating profit KRW 104bn
- Segments · Pharma (prescription and OTC drugs) 64.1% · Overseas (exports and Yuhan Chemical APIs) 17.7% · Healthcare (Yuhan Lox and household goods) 9.9% · License income (Lazertinib etc.) 4.8%
Revenue from
- 길리어드 사이언스 (원료의약품 공급) High confidence· Amount ₩210.2B · HIV 원료 공급계약
Subsidiary Yuhan Chemical supplies HIV and hepatitis C (HCV) active pharmaceutical ingredients (APIs) to Gilead. HIV API contract KRW 210.2bn (US$139.8m, 9.61% of 2025 consolidated revenue, 2026.05.19); HCV API contract KRW 85.0bn (US$61.3m, 2025.08.26). - 브리지바이오 파마 (심근병증 원료의약품 공급) High confidence· Amount ₩56B · 심근병증 원료 공급계약
Supplies cardiomyopathy-drug API to BridgeBio Pharma. Contract KRW 56.0bn (US$38.1m, 2.56% of 2025 consolidated revenue, 2026.05.05 to 2028.03.01).Confirms KO FSS DART Published May 6, 2026: Single Supply Contract (cardiomyopathy API supply, BridgeBio) - 존슨앤드존슨 (얀센, 렉라자 라이선스아웃) High confidence· Amount $950M · 총 기술수출 규모(정정)
Out-licensed Lazertinib to Janssen Biotech in 2018. Current deal size US$950m (revised down from US$1.255bn on 2024.09.20 after the 4th-gen EGFR co-development ended); US$50m upfront plus milestones. J&J's Rybrevant plus Lazcluze combo approved in the US (2024.08), Europe (2025.01), Japan (2025.03) and China (2025.07), driving net-sales royalties. License income was KRW 104.1bn in 2025 (4.8% of revenue).Confirms KO Edaily (Shinhan Securities) Published May 28, 2026: Shinhan cuts Yuhan target on soft Lazertinib royalties, keeps long-term viewMentions KO Asiae (KB Securities) Published May 27, 2026: Yuhan royalty inflow to accelerate, target KRW 125,000 (KB Securities)Confirms EN Johnson & Johnson Investor News Published May 31, 2025: RYBREVANT plus LAZCLUZE prevents acquired resistance vs osimertinib in first-line EGFR-mutated NSCLC
Pays to
- Cheplapharm Arzneimittel GmbH (아타칸 수입) High confidence· Amount ₩13.4B · 아타칸 매입액
Imports the hypertension drug Atacand (candesartan) from Germany's Cheplapharm. 2025 purchases KRW 13.4bn (Atacand 8mg KRW 7.66bn plus 16mg KRW 5.73bn), the largest imported raw-material item. - 오스코텍 (렉라자 원개발사 기술료 배분) High confidence
The original technology developer of Lazertinib. Yuhan shares part of the upfront, milestones and royalties received from Janssen with Oscotec and Genosco (commonly reported as a 6:4 split), booked as an expense. - 국전약품 (에제티미브 원료) Medium confidence· Amount ₩6.4B · 에제티미브 매입액
Buys ezetimibe, the API for its hyperlipidemia drug Rosuvamibe, from Kukjeon Pharm and Yuhan Chemical. 2025 ezetimibe purchases KRW 6.4bn (5.1% of domestic raw materials). - ALMIRALL S.A (알마게이트 원료) Medium confidence· Amount ₩5.3B · 알마게이트 매입액
Imports the antacid ingredient almagate from Spain's Almirall S.A. 2025 purchases KRW 5.3bn (4.2% of imported raw materials); period-end price EUR 11.00/kg.
Value-chain ripple (2 tiers)
Following node-to-node links up to 2 tiers; each firm is shown once, at its nearest tier.
| Company | Chain | '21 | '22 | '23 | '24 | '25 | YTD |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson | lead1 | +11.4 | +6 | -8.6 | -4.8 | +47.5 | +25.6 |
| Gilead Sciences | lead1 | +30 | +23.6 | -2 | +18.7 | +36.6 | +7.1 |
| Yuhan Corporation | node | -9 | -2.3 | +19.7 | +119.9 | -16.7 | -36.2 |
| Oscotec | benef1 | -17 | -38.1 | -0.3 | +39.8 | +108.2 | -44.2 |
YTD as of 2026-07-10 · source: Yahoo Finance
The core question for Yuhan is two high-leverage growth options layered on a mature domestic-pharma cash cow. First is Lazertinib — as J&J's Rybrevant-plus-Lazcluze combo wins sequential approvals in the US, Europe, Japan and China, net-sales royalties flow in with almost no cost, so rising uptake converts straight into profit leverage (part of the upfront, milestones and royalties is shared with Oscotec and Genosco). Second is subsidiary Yuhan Chemical's API exports, where large contracts to Gilead (HIV/HCV) and BridgeBio (cardiomyopathy) drive the overseas business. In graph terms Yuhan is a revenue node to global pharma (J&J, Gilead, BridgeBio) and a cost node to Oscotec and Genosco, so the global sales curve of the Lazertinib combo is the biggest swing factor for valuation.
Analysis generated from returns as of 2026-07-10